Recurrent Endometrial Carcinoma
Conditions
Keywords
metformin, endometrial cancer
Brief summary
Given the early literature available and its biological plausibility as an inhibitor of the mammalian target of rapamycin (mTOR) protein, it is hypothesized that women with endometrial cancer who take metformin for non-cancer related reasons have a lower cancer recurrence rate compared to women not taking metformin. The primary goal of this study is to determine whether metformin use is associated with a decrease in the rate of endometrial cancer recurrence. Secondary objectives are to assess whether women with endometrial cancer taking metformin have longer progression free survival and overall survival than those that do not take metformin.
Detailed description
This is a retrospective chart review study. Medical records are reviewed and data collected through the hospital's electronic medical record (EMR). Participants are women that had definitive treatment for endometrial cancer between 2016-2020 at WellSpan York Hospital Department of Gynecologic Oncology. Participants are identified and their chart reviewed for demographic data of age, race, comorbid conditions, and use of metformin. Possible confounding information is documented, including chemotherapy status, radiotherapy status, cancer and tumor type, grade, and stage, available genetics information, medications at the time of cancer diagnosis, and medication durations. Those patients who had cancer recurrence are identified. Recurrence data including type, time interval, additional treatment are collected. Recurrence is defined as any recurrence validated by clinical, imaging and histological data and can be identified based on the cancer registry. Recurrence rate in participants that took metformin vs. those that did not is calculated. Time to endometrial cancer recurrence is calculated. Progression free survival and overall survival are calculated. Statistical analysis is performed to compare each of these outcomes between participants who took metformin vs. those that did not.
Interventions
DRUGMetformin use
As an observational study, this is past exposure to metformin that occurred during the study period
Sponsors
WellSpan Health
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 99 Years
Healthy volunteers
Yes
Inclusion criteria
* Participants with endometrial cancer of all histologies treated in the WellSpan system from 2016-2020
Exclusion criteria
* Participants who underwent palliative treatment for endometrial cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Endometrial Cancer Recurrence | 2016-2020 | This is the identification of whether metformin use is associated with endometrial cancer recurrence. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | 2016-2020 | This is the identification of whether metformin use is associated with improved progression free survival of endometrial cancer. |
| Overall Survival | 2016-2020 | This is the identification of whether metformin use is associated with improved overall survival of endometrial cancer. |
Countries
United States
Outcome results
None listed